White Papers

  1. On A Technology–Enabled Collision Course: Clinical Research And Clinical Practice Converge Through Real World Evidence

    Late Phase Research in the Life Sciences segment is undergoing a rapid transformation due to the digitalisation of healthcare and the greater availability of, and access to, Real World Data (RWD). This transformation is arriving not a moment too soon, given the changes anticipated from the Twenty-first Century Cures Act, EMA’s Adaptive Pathways approach, and the increased demand for Real World Evidence (RWE) generated from these RWD. In addition to supporting regulatory decisions, RWE is playing an ever expanding role in developing the product value propositions that are driving reimbursement decisions globally.

  2. New Opportunities For Immuno-oncology Clinical Development Programs Through T Cell/B Cell Repertoire Profiling

    Immune repertoire profiling provides better outcomes for immuno-oncology development programs .

  3. Analytics And Metrics Help Pinpoint Costs Of Study Startup

    Learn how by embracing a systematic, data-driven approach, it is possible for metrics to identify more accurately the best sites, steps causing delays, the associated costs, and why this is happening.

  4. More Collaboration With Investigative Sites: Less Technology Overload Delivers Transparency And Efficiencies

    Learn about how sites struggling under the weight of too much technology, yet looking for a more robust collaboration and transparency process can benefit from automated workflows in the initiation of clinical trials.

  5. Adopting eConsent In Research: Security, Privacy, And Other Considerations

    This whitepaper offers a résumé of regulations under which eConsent solutions and vendors may fall and, more importantly, discusses the practical implications of those regulations for vendors and those responsible for designing and executing research plans.

  6. Minimal Residual Disease Detection: Key Considerations For Clinical Development In Oncology

    Current MRD detection landscape, key considerations for each approach, and current advancements that will contribute to further improvements in MRD detection.

  7. Harnessing Innovative Technologies For Clinical Trials Involving Emerging And Re-Emerging Infectious Diseases

    This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola.

  8. Shifting From One Drug For All Patients To Personalized Genomics-Based Therapeutic Options

    Discover how a comprehensive personalized genomics strategy can help you identify the patients who would most likely benefit from a treatment and suffer the least side effects, ensuring the right drug is used in the right patient at the right time.

  9. Translating Data Into Insights With Bioinformatics

    Learn what bioinformatics offers to precision medicine and immuno-oncology.

  10. Minimal Residual Disease: Finding The Right Test For The New Definition Of Remission

    Measurement of Residual Disease for improved oncology trial outcomes - what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.